CytomX Therapeutics, Inc.
CTMX
$3.36
$0.010.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -87.03% | -75.91% | -44.82% | -10.26% | 18.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -87.03% | -75.91% | -44.82% | -10.26% | 18.01% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -87.03% | -75.91% | -44.82% | -10.26% | 18.01% |
| SG&A Expenses | 4.57% | -4.46% | -3.33% | -11.99% | -3.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.78% | -12.72% | -15.33% | -24.62% | -13.94% |
| Operating Income | -295.60% | -272.02% | -178.28% | 246.44% | 653.67% |
| Income Before Tax | -264.67% | -240.79% | -153.38% | 87.67% | 219.88% |
| Income Tax Expenses | -6.85% | -0.85% | 6.28% | -80.08% | -93.79% |
| Earnings from Continuing Operations | -266.00% | -242.16% | -154.50% | 102.59% | 332.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -266.00% | -242.16% | -154.50% | 102.59% | 332.83% |
| EBIT | -295.60% | -272.02% | -178.28% | 246.44% | 653.67% |
| EBITDA | -286.61% | -261.02% | -167.96% | 186.81% | 486.76% |
| EPS Basic | -182.22% | -175.80% | -97.70% | 138.57% | 301.66% |
| Normalized Basic EPS | -175.47% | -167.96% | -88.25% | 120.28% | 197.87% |
| EPS Diluted | -183.12% | -177.32% | -99.01% | 143.38% | 316.39% |
| Normalized Diluted EPS | -175.49% | -167.98% | -88.21% | 121.82% | 199.83% |
| Average Basic Shares Outstanding | 88.85% | 86.98% | 63.11% | 39.99% | 17.57% |
| Average Diluted Shares Outstanding | 88.78% | 86.90% | 62.77% | 39.70% | 17.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |